Skip to main content

TNF inhibitor

TNF Inhibitor Associated Infectious Risk Greatest in First 6 Months https://t.co/fMF71rMAn8 https://t.co/mlFFb2m4UE
Dr. John Cush RheumNow ( View Tweet)
Nov 19, 2020
Download our 2020 TNF Inhibitor Biosimilars worksheet. https://t.co/whebbA3Ucv https://t.co/Bm5rgBPKkH
Dr. John Cush RheumNow ( View Tweet)
Nov 19, 2020
Download our 2020 TNF Inhibitor Biosimilars worksheet. https://t.co/whebbA3Ucv https://t.co/6t6Vu23Gmb
Dr. John Cush RheumNow ( View Tweet)
Nov 18, 2020
Read more on Racial disparities in Bilateral Knee Arthroplasty in Osteoarthritis by Dr. Bella Mehta ( @bella_mehta) #ACR20 https://t.co/yataL7H8X4 https://t.co/JBM8V6OX8J
Dr. John Cush RheumNow ( View Tweet)
Nov 14, 2020

Rheumatology Round-Up with Drs. Kavanaugh & Cush

Nov 10, 2020

The Annual Review of Best ACR 2020 abstracts featuring Drs. Cush and Kavanaugh filmed on the last day of Virtual ACR 2020 Nov. 9, 2020. Watch now!


Read Article
What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumatoid nodules. Pt has been on triple csDMARDs + Leflunomide, then 2 JAKi and 2 TNFi also with MTX each time. All Rx works for 6 months then relapse.
Janet Pope Janetbirdope ( View Tweet)
Nov 09, 2020
Dr Lillegraven presents a randomized open-label phase 4, non-Inferiority trial of TNFi tapering in RA patients in sustained remission. 63% of tapered patients flared over 12 months vs 5% of maintained.
Richard Conway RichardPAConway ( View Tweet)
Nov 09, 2020

Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms @RheumNow #ACR20 Abs#2026 https://t.co/OHzIjXKqAu

Robert B Chao, MD doctorRBC ( View Tweet)
Nov 09, 2020
Draft #ACR20 Rx Recommendations for RA: MTX monotherapy conditionally rec over csDMARD dual or triple Rx, MTX+TNFi @RheumNow https://t.co/jyjRD5aadN
Eric Dein ejdein1 ( View Tweet)
Nov 09, 2020
European Rheum Consortium (SHARE) recommendations for Rx of systemic JIA: 1) Systemic JIA - AOSD; 2) STEROIDs, 3) IL-1 inhibitors; 4) TCZ, 5) MTX & TNFi mainly for arthritis. Should be aware of risk for MAS and ILD #ACR20 Abstr#1148 https://t.co/mgZvLKNljs

Dr. John Cush RheumNow ( View Tweet)

Nov 08, 2020

Network Meta-Analysis of JAK and TNF Inhib in 19 AS studies (3,654pts) showed best results with TNFi (golimumab and infliximab) but JAKs also appear to be effective option.

Dr. John Cush RheumNow ( View Tweet)
Nov 08, 2020

1yr results using anti-IL-23 Guselkumab shows the same ACR 20/50/70 responses regardless of prior TNF inhibitor failure. #ACR20 #Abstr#1344 https://t.co/OvgJ53wwmU https://t.co/JdajDONWap

Dr. John Cush RheumNow ( View Tweet)
Nov 08, 2020

ACR20 - Day 2 Report

Nov 08, 2020

Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two:

Read Article
For all your nr-axSpA fanatics, there's a fantastic poster on certolizumab response in nr-axSpA stratified by MRI and CRP status #ACR20 @steverheum_hall https://t.co/WI1vdMItUO https://t.co/JnvAyyClDu
Dr Philip Robinson philipcrobinson ( View Tweet)
Nov 08, 2020
Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort https://t.co/ZzhE0J7dOX #TOFA #TNFi TNFi does better with MTX Tofa less necessary

Peter Nash drpnash ( View Tweet)

Nov 07, 2020

Etanercept monotherapy significantly more effective than Methotrexate monotherapy in maintaining remission in RA patients on combination therapy. Data from the SEAM-RA study @RheumNow #ACR20 Abstr#0939 #ACRbest

Dr. Antoni Chan synovialjoints ( View Tweet)

Nov 07, 2020

After the SEAM-RA study, in patients taking MTX and ETN in sustained remission would you? #ACR20 @rheumnow

Richard Conway RichardPAConway ( View Tweet)

Nov 07, 2020

SEAM-RA trial Abst#0939 Combo TNF/MTX Rx -> ETN monoRx superior to MTX monoRx in sustaining remisson, simliar to staying on combo Rx. #ACR20 @RheumNow. Benefit of continuing combo: protect HACA Ab and longevity of TNFi https://t.co/Q934naKnBq

Eric Dein ejdein1 ( View Tweet)
Nov 07, 2020

Another biosimilar Adalimumab. SB5 switch in RA, PsA & SpA N=354 No diff in effectiveness Some minor flares. Some changed dose unsure why. #ACR2020 @RheumNow @CRASCRRheum abstr#805 https://t.co/2Zb4H2jBXQ

Janet Pope Janetbirdope ( View Tweet)
Nov 07, 2020
MEASURE2 and COAST-W data stratified by TNFi inadequate responders may suggest different axSpA subset (domain?) response to TNFi vs IL17i. Dr. J. Ermann #ACR20 @RheumNow #ACRbest https://t.co/0ZcEIvkuMj
Dr. Rachel Tate uptoTate ( View Tweet)
Nov 07, 2020
OBRI Canadian registry showed real world retention data for Tofa and TNFi are both similar, but RA pts on TNFi w/o MTX d/c drug more compared to those who stay on MTX (does not matter with Tofa if they are on MTX) Abstr#808 #ACR20 @rheumnow https://t.co/TDmV0EJTp
Nov 07, 2020

SEAM-RA: SDAI remission greater in pts on ETN alone vs. MTX alone; ⬆ pts in remission w/ combined tx vs. MTX alone. These may guide tx decisions re withdrawal in well-controlled RA @Rheumnow #ACR20 https://t.co/33GhuMuL3I

Nov 07, 2020
Never forget how far we have come in rheumatology therapeutics, in a very short period of time. Some of the original slides that Tiny Maini and Marc Feldmann used. @r_burmester giving the Phillip Hench Lecture #ACR20 @RheumNow https://t.co/YI32BX2iw8
David Liew drdavidliew ( View Tweet)
Nov 07, 2020

Which Adalimumab biosimilar to use (if any)? The race is on to have 1st Ada or 2nd reimbursed/preferentially listed in US reimbursement plans & dare I say it mandatory switching like in Europe.

Janet Pope Janetbirdope ( View Tweet)
Nov 07, 2020
×